Operating Segments (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Summary of segmental information
Total revenues	$ 910,597	$ 900,354
Income/ (Loss) from Operations	(1,589,909)	(1,087,897)
Amortization and Depreciation Expense	62,087	56,498
Interest Income	291	483
Stock-Based Compensation	176,662	79,492
Identifiable Assets	7,012,973		8,265,455
Vaccines/BioDefense [Member]
Summary of segmental information
Total revenues	877,045	829,849
Income/ (Loss) from Operations	139,404	(30,995)
Amortization and Depreciation Expense	9,935	27,667
Stock-Based Compensation	10,450	11,121
Identifiable Assets	948,567		1,870,414
BioTherapeutics [Member]
Summary of segmental information
Total revenues	33,552	70,505
Income/ (Loss) from Operations	(1,035,591)	(457,625)
Amortization and Depreciation Expense	49,939	28,395
Stock-Based Compensation	76,121	21,036
Identifiable Assets	339,502		386,721
Corporate [Member]
Summary of segmental information
Income/ (Loss) from Operations	(693,722)	(599,277)
Amortization and Depreciation Expense	2,213	436
Interest Income	291	483
Stock-Based Compensation	90,091	47,335
Identifiable Assets	$ 5,724,904		$ 6,008,320